RA Capital Management - CATABASIS PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
RA Capital Management ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$12,550,0005,947,8610.20%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Soleus Capital Management, L.P. 775,000$2,240,0000.40%
SPHERA FUNDS MANAGEMENT LTD. 1,294,000$3,740,0000.29%
ArchPoint Investors 162,826$471,0000.13%
Ikarian Capital, LLC 852,998$2,464,0000.08%
Samsara BioCapital, LLC 150,000$434,0000.08%
Perceptive Advisors 1,933,551$5,588,0000.07%
Fairmount Funds Management LLC 53,166$154,0000.06%
Alyeska Investment Group, L.P. 1,124,623$3,250,0000.04%
Alyeska Investment Group, L.P. 731,303$2,113,0000.03%
Corient Capital Partners, LLC 103,523$299,0000.03%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders